Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05596006 |
Other study ID # |
KE/FK/0191/EC/2022 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
December 31, 2022 |
Est. completion date |
March 24, 2023 |
Study information
Verified date |
March 2023 |
Source |
Gadjah Mada University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is assess the efficacy of ASIMOMMY® in increasing breast milk
production in postpartum mothers.
Description:
Several traditional herbs have been used and is well known since a long time ago by
Indonesian people to increase the production of breastmilk, such as Katuk leaves (Sauropus
androgynous Folium), Fenugreek (Trigonella foenum-graceum), and Moringa leaves (Moringa
oleifera Folium). These plants have been scientifically proven through preclinical and even
clinical research. However, not many have been further developed as phytopharmaceuticals that
can be used in formal health services.
In previous research, ASI MOMMY® capsules have been successfully produced in accordance to
the traditional method of making good herbal drugs, with each capsule containing extracts of
Katuk leaf (300 mg), Fenugreek (150 mg), and Moringa leaf (50 mg). This formulation has gone
through pharmacodynamic activity test, and acute and subactute toxicity test. Research has
shown that ASI MOMMY® is works actively as a galactogogue and is not toxic, therefore it is
safe to be given to humans (unpublished),
No research has been done to test the benefits of ASI MOMMY® in increasinng breastmilk
production. Therefore, this research is a clinical trial that intends to see the benefits of
ASI MOMMY® for increasing breastmilk production in postpartum women. This research is a part
of the previous main research that is still ongoing to this day which aims to develop the
formulation of ASI MOMMY® as a phytopharmaceutical